| Bioactivity | Exidavnemab (ABBV-0805; BAN-0805) is a human IgG4 monoclonal antibody that selectively targets soluble human α-synuclein aggregates with a KD value of 18.5 pM and a KD value of 2.2 μM for α-synuclein monomers. Exidavnemab is used in Parkinson's disease research[1]. |
| Invitro | ABBV-0805 可以以剂量依赖的方式增强小鼠原代神经元细胞活力，在高剂量下，细胞活力可达到 81.4 % 左右[1]。 |
| Name | Exidavnemab |
| CAS | 2438229-02-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Eva Nordström, et al. ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease. Neurobiol Dis. 2021 Dec;161:105543. |